Dr. Victoria Chua-Alcala, MD
Claim this profileSarcoma Oncology Research Center
Expert in Lymphoma
Expert in Cancer
44 reported clinical trials
63 drugs studied
About Victoria Chua-Alcala, MD
Education:
- Earned a Medical degree (MD) from an unspecified institution.
Experience:
- Serves as a clinical researcher at the Sarcoma Oncology Research Center.
- Involved in the GALLANT study (NCT04535713), a phase 2 clinical trial for advanced sarcoma.
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
0
2Cancer
Global LeaderStage IV
Stage III
KRAS positive
Affiliated Hospitals
Sarcoma Oncology Research Center
Sarcoma Oncology Center
Clinical Trials Victoria Chua-Alcala, MD is currently running
Chemotherapy + Immunotherapy
for Advanced Sarcoma
This trial uses a combination of chemotherapy and immunotherapy to treat patients with advanced sarcoma. The chemotherapy attacks the cancer directly, while the immunotherapy boosts the body's natural defenses to help fight the cancer.
Recruiting1 award Phase 212 criteria
Bria-OTS Immunotherapy
for Breast Cancer
This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.
Recruiting1 award Phase 1 & 27 criteria
More about Victoria Chua-Alcala, MD
Clinical Trial Related6 years of experience running clinical trials · Led 44 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Victoria Chua-Alcala, MD has experience with
- Nivolumab
- Gemcitabine
- Trabectedin
- SM-88
- Doxorubicin
- Pembrolizumab
Breakdown of trials Victoria Chua-Alcala, MD has run
Lymphoma
Cancer
Solid Tumors
Soft Tissue Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Victoria Chua-Alcala, MD specialize in?
Victoria Chua-Alcala, MD focuses on Lymphoma and Cancer. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Victoria Chua-Alcala, MD currently recruiting for clinical trials?
Yes, Victoria Chua-Alcala, MD is currently recruiting for 12 clinical trials in Santa Monica California. If you're interested in participating, you should apply.
Are there any treatments that Victoria Chua-Alcala, MD has studied deeply?
Yes, Victoria Chua-Alcala, MD has studied treatments such as Nivolumab, Gemcitabine, Trabectedin.
What is the best way to schedule an appointment with Victoria Chua-Alcala, MD?
Apply for one of the trials that Victoria Chua-Alcala, MD is conducting.
What is the office address of Victoria Chua-Alcala, MD?
The office of Victoria Chua-Alcala, MD is located at: Sarcoma Oncology Research Center, Santa Monica, California 90403 United States. This is the address for their practice at the Sarcoma Oncology Research Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.